SCHEMBL2477449

SCHEMBL2477449

CCN(CC)c1ccc2cc3ccc(N(CC)CC)cc3[o+]c2c1.O=[N+]([O-])[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 1/20 0.50
ALDH1A1 P00352 11/20 0.43
MEN1 O00255 10/20 0.43
KMT2A Q03164 10/20 0.43
MAPT P10636 9/20 0.43
KDM4E B2RXH2 6/20 0.43
L3MBTL1 Q9Y468 6/20 0.43
LMNA P02545 2/20 0.43
GLA P06280 1/20 0.43
CYP19A1 P11511 1/20 0.41
HPGD P15428 4/20 0.38
NPSR1 Q6W5P4 1/20 0.38
S100B P04271 1/20 0.38
HSD17B10 Q99714 3/20 0.37
MAPK1 P28482 3/20 0.37
ALDH3A1 P30838 1/20 0.37
ALDH1A3 P47895 1/20 0.37
ATM Q13315 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALOX15 P16050 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL94357 0.88 TERT (0.58) TERTALDH1A1MEN1KMT2AMAPT
Bromide SCHEMBL2477887 0.88 TERT (0.58) TERTALDH1A1MEN1KMT2AMAPT
Hydrochloric Acid SCHEMBL2477629 0.86 TERT (0.56) TERTALDH1A1MEN1KMT2AMAPT
Hydrochloric Acid SCHEMBL2479389 0.86 TERT (0.56) TERTALDH1A1MEN1KMT2AMAPT
SCHEMBL2475541 0.81 MAPT (0.46) TERTALDH1A1MEN1KMT2AMAPT
SCHEMBL11269090 0.75 TERT (0.50) TERTALDH1A1MEN1KMT2AMAPT
SCHEMBL2477241 0.74 ALDH1A1 (0.39) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL29549001 0.73 TERT (0.61) TERTALDH1A1MEN1KMT2AMAPT
SCHEMBL3899512 0.73 TERT (0.61) TERTALDH1A1MEN1KMT2AMAPT
Hydrochloric Acid SCHEMBL31741233 0.71 TERT (0.59) TERTALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3689346-A1 3,6-DISUBSTITUTED XANTHYLIUM SALTS WisTa Laboratories Ltd. (SG) 2020-08-05 EP claimed
EP-3112358-A2 3,6-DISUBSTITUTED XANTHYLIUM SALTS WisTa Laboratories Ltd. (SG) 2017-01-04 EP claimed
EP-2373660-A2 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS Wista Laboratories Ltd. (SG) 2011-10-12 EP claimed
WO-2010067078-A2 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS WISTA LABORATORIES LTD. (SG) 2010-06-17 WO claimed
EP-4327874-A2 3,6-DISUBSTITUTED XANTHYLIUM SALTS WisTa Laboratories Ltd. (SG) 2024-02-28 EP disclosed
EP-3689346-B1 3,6-DISUBSTITUTED XANTHYLIUM SALTS FOR TREATING TAUOPATHIES WISTA LAB LTD (SG) 2024-01-24 EP disclosed
EP-3689346-A1 3,6-DISUBSTITUTED XANTHYLIUM SALTS WisTa Laboratories Ltd. (SG) 2020-08-05 EP disclosed
EP-3112358-B1 3,6-DISUBSTITUTED XANTHYLIUM SALTS WISTA LAB LTD (SG) 2020-04-29 EP disclosed
US-10399955-B2 3,6-disubstituted xanthylium salts WISTA LABORATORIES LTD. (SG) 2019-09-03 US disclosed
US-20170088534-A1 3,6-DISUBSTITUTED XANTHYLIUM SALTS WISTA LABORATORIES LTD. (SG) 2017-03-30 US disclosed
US-9549933-B2 3,6-disubstituted xanthylium salts WISTA LABORATORIES LTD. (SG) 2017-01-24 US disclosed
EP-3112358-A2 3,6-DISUBSTITUTED XANTHYLIUM SALTS WisTa Laboratories Ltd. (SG) 2017-01-04 EP disclosed
EP-2373660-B1 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS WISTA LAB LTD (SG) 2016-08-17 EP disclosed
US-20140161731-A1 3,6-DISUBSTITUTED XANTHYLIUM SALTS WISTA LABORATORIES LTD. (SG) 2014-06-12 US disclosed
EP-2373660-A2 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS Wista Laboratories Ltd. (SG) 2011-10-12 EP disclosed
WO-2010067078-A2 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS WISTA LABORATORIES LTD. (SG) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140161731-A1 3,6-DISUBSTITUTED XANTHYLIUM SALTS MAPT, PSEN2, PSEN1 TERT 1191/4885ALDH1A1 4669/4885MEN1 2597/4885
US-10399955-B2 3,6-disubstituted xanthylium salts MAPT, PSEN2, PSEN1 TERT 1191/4885ALDH1A1 4669/4885MEN1 2597/4885
US-20170088534-A1 3,6-DISUBSTITUTED XANTHYLIUM SALTS MAPT, PSEN2, PSEN1 TERT 1191/4885ALDH1A1 4669/4885MEN1 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.